SVNS — Solvonis Therapeutics Balance Sheet
0.000.00%
- £3.50m
- £2.74m
- 24
- 22
- 43
- 17
Annual balance sheet for Solvonis Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 May 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Cash and Equivalents | ||||
Cash and Short Term Investments | 0.545 | 1.64 | 0.155 | 0.757 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 0.112 | 0.33 | 0.087 | 0.036 |
Total Inventory | ||||
Prepaid Expenses | ||||
Total Current Assets | 0.657 | 2.16 | 0.314 | 0.815 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | — | 0.701 | 0.039 | 0 |
Net Intangible Assets | ||||
Long Term Investments | ||||
Long Term Notes Receivable | ||||
Other Long Term Assets | ||||
Total Assets | 4.33 | 4.94 | 2.43 | 3.2 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 1.91 | 0.367 | 0.386 | 0.119 |
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Liabilities | 1.91 | 0.385 | 0.408 | 0.119 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | 2.43 | 4.55 | 2.03 | 3.08 |
Total Liabilities & Shareholders' Equity | 4.33 | 4.94 | 2.43 | 3.2 |
Total Common Shares Outstanding |